BEAM Share Price Performance
US$29.61
1.72 (6.17%)
80.3% undervalued intrinsic discount
US$150.00
Fair Value
Price US$29.61
davidlsander US$150.00
AnalystConsensusTarget US$47.21
AnalystLowTarget US$22.00
Fair ValueUS$150.00
Share Pricen/a
Beam Therapeutics Inc. Stock Price
- 3 Narratives written by author
- 3 Comments on narratives written by author
- 129 Fair Values set on narratives written by author
BEAM Community Narratives
DA
Fair Value US$150 80.3% undervalued intrinsic discount
The "Molecular Pencil": Why Beam's Technology is Built to Win
12users have liked this narrative
3users have commented on this narrative
70users have followed this narrative
AN
Fair Value US$49.73 40.5% undervalued intrinsic discount
Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases
0users have liked this narrative
0users have commented on this narrative
52users have followed this narrative
AN
Fair Value US$22 34.6% overvalued intrinsic discount
Base Editing Platform And PKU Umbrella Trials Will Struggle To Justify Long Runway
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
The "Molecular Pencil": Why Beam's Technology is Built to Win
The "Molecular Pencil": Why Beam's Technology is Built to Win The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool.Read more
9.1k
users have viewed this narrative12users have liked this narrative
3users have commented on this narrative
70users have followed this narrative
DA
US$150
80.3% undervalued intrinsic discount
davidlsander's Fair Value
Revenue
295.2% p.a.
Profit Margin
21.34%
Future PE
30.21x
Price in 2028
US$183.38
Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases
Key Takeaways Promising programs in genetic diseases and innovative technology could significantly boost market share and revenue potential. Strategic advancements in gene editing could expand patient access and drive revenue growth through broader treatment availability.Read more
666
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
52users have followed this narrative
AN
US$49.73
40.5% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
-2.36% p.a.
Profit Margin
12.72%
Future PE
425.4x
Price in 2029
US$60.81
Base Editing Platform And PKU Umbrella Trials Will Struggle To Justify Long Runway
Catalysts About Beam Therapeutics Beam Therapeutics develops base editing genetic medicines that aim to provide onetime treatments for serious diseases such as sickle cell disease, alpha-1 antitrypsin deficiency and phenylketonuria. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$22
34.6% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
-38.91% p.a.
Profit Margin
15.44%
Future PE
1.41kx
Price in 2029
US$27.06
Trending Discussion
Recently Updated Narratives
DA
Next Milestones For Beam in 2026.
Fair Value: US$150 80.3% undervalued intrinsic discount
70 followersusers have followed this narrative
3 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BEAM: FDA Program Alignment On Sickle Cell Will Drive Future Repricing
Fair Value: US$49.73 40.5% undervalued intrinsic discount
52 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Base Editing Platform And PKU Umbrella Trials Will Struggle To Justify Long Runway
Fair Value: US$22 34.6% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Beam Therapeutics Inc. Key Details
About BEAM
- Founded
- 2017
- Employees
- 510
- CEO
- WebsiteView website
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
